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Abstract 
In this article, we review the evidence suggesting a possible role for B19 virus in the pathogenesis of a subset of 
cases of acute leukemia. Human parvovirus B19 infection may complicate the clinical course of patients with 
acute leukemia, and may also precede the development of acute leukemia by up to 180 days. Parvovirus B19 
targets erythroblasts in the bone marrow, and may cause aplastic crisis in patients with shortened red cell 
survival. Aplastic crisis represents a prodrome of ALL in 2% patients. There is significant overlap between those 
HLA class I and II alleles which are associated with a vigorous immune response and development of symptoms 
during B19 infection, and those HLA alleles which predispose to development of acute leukemia. Acute 
symptomatic B19 infection is associated with low level of circulating IL-10 consistent with a vigorous immune 
response; deficient IL-10 production at birth was recently found to be associated with subsequent 
development of acute leukemia. Anti-B19 IgG has been associated with a particular profile of methylation of 
human cancer genes in patients with acute leukemia, suggesting an additional hit and run mechanism. The 
proposed role for parvovirus B19 in the pathogenesis of acute leukemia fits very well with the delayed infection 
hypothesis and with the 2-step mutation model, which describes the carriage of the first mutation prior to 
birth, followed by suppression of haematopoiesis, which allows rapid proliferation of cells harbouring the first 
mutation, acquisition of a second activating mutation, and expansion of cells carrying both mutations, resulting 
in a clinical presentation of acute leukemia. 
 
Keywords: Human parvovirus B19, acute leukemia, acute lymphoblastic leukemia, acute myeloblastic 
leukemia, cytopenia, erythrotropism, aplastic crisis, pancytopenia, HLA, cytokine. 
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Introduction 
Acute childhood leukemia accounts for most cases of childhood cancer and its cause, or causes, are not yet 
understood, although modern treatment regimens are often successful. Many candidate environmental 
exposures have been proposed, however, most of these lack epidemiological evidence and plausible biological 
mechanisms. Significant evidence supports the role of infection and immunity in the pathogenesis of acute 
childhood leukemia, however, it is not clear whether one or more infectious agents are involved[1].  
Human parvovirus B19 is a single-stranded DNA virus which replicatesprimarily in the erythroblasts in the bone 
marrow and it has been shown to persist life-long in many different cell types throughout the body following 
acute infection[2]. B19 infection commonly causes erythema infectiosum, arthralgia, fetal death, transient 
aplastic crisis in patients with shortened red cell survival, and persistent infection in immunocompromised 
persons. Less common clinical manifestations include atypical skin rashes, neurological syndromes, cardiac 
syndromes, and various cytopenias resulting from bone marrow infection[2,3]. 
B19 infection has also been demonstrated to occur in the setting of acute leukemia. This has been thought to 
represent either reactivation of latent B19 virus due to immunosuppression or due to coincidental acquisition 
of B19 virus in the context of acute leukemia during cytotoxic treatment. But more interestingly, there have 
been a significant number of case reports of acute leukemia with documented acute B19 infection occurring 
either before or at the time of diagnosis of acute leukemia, suggesting the possibility that B19 virus may 
contribute to the pathogenesis of acute leukemia in some way.  
In this review, we review all published cases of B19 infection associated with acute leukemia, occurring both 
before and after the diagnosis of acute leukemia, studies of B19 infection in leukemia, parallels between the 
pathogenesis of acute leukemia and that of B19 infection, the particular features of B19 infection which 
highlight its potential as a candidate trigger infection in the pathogenesis of acute leukemia, consideration of 
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other childhood virus infections which have been associated with acute leukemia, and recommendations for 
future research. 
 
Case reports of B19 infection in patients with acute leukemia during chemotherapy 
Table 1 summarises the clinical course of 29 patients with acute leukemia in whom B19 infection was 
documented during chemotherapy. The age range of these patients was 1 – 65 years, with 13 males, 15 
females and one of unknown sex. There were 17 patients with acute lymphoblastic leukemia (ALL), 2 patients 
with B cell ALL, 6 patients with pre-BALL, one patient with acute myeloblastic leukemia (AML) type M6b, 2 
patients with LGLL and one patient with CTCL. The interval between diagnosis of leukemia and onset of B19 
infection ranged from 14 days to 14 years. B19 infection resulted in some degree of anemia in all patients, 
which ranged from mild to severe; thrombocytopenia was documented in 13 patients, lymphocytopenia in one 
patient and neutropenia in 2 patients. B19 infection was not treated in 5 patientsand treatment was 
undisclosed for 2 patients. Five patients received intravenous immunoglobulin (IVIG) alone, while 8 patients 
received both IVIG and red cell transfusion. Five patients received red cell transfusion alone, while 3 patients 
were treated by stopping chemotherapy. There were no deaths due to B19 infection and all patients recovered 
with or without specific treatment.  
 
Case reports of B19 infection in patients with acute leukemia prior to or at the time of diagnosis 
Table 2 summarises the clinical course of 16 patients with acute leukemia in which B19 infection was 
documented prior to or at the time of diagnosis of acute leukemia. There were 6 males and 10 females. Among 
15 of the 16 patients, the ages ranged from 1 to 33 years, and the 16th patient was 69 years old. There was a 
B19-associated prodrome consisting of aplastic crisis in 7 of 16 patients which occurred 14 – 180 days prior to 
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the diagnosis of leukemia.Detection of B19 infection in the remaining 9 patients without a prodrome of aplastic 
crisis, occurred 0 – 3 days before the diagnosis of acute leukemia. All 16patients except one (No. 3) had anemia 
at presentation, which ranged from mild to severe. Patient no. 3 also stands out as having a different clinical 
presentation from the others, in that this was the only patient to present with neurological symptoms. 
Evidence of acute B19 infection at presentation consisted of detection of either anti-B19 IgM or DNA, or both, 
except in the case of patient no. 10, who did not have specific B19 testing performed.However, this case had a 
prodrome of aplastic crisis, a rash resembling erythema infectiosum, anemia, erythroid hypoplasia on bone 
marrow testing, and other presenting symptoms typical of B19 infection. Bone marrow was examined in 13 of 
16 cases, and each of these 13patientsexhibited at least one of the following recognized signs of B19 infection; 
erythroid hypoplasia, pancytopenia and giant pronormoblasts. Regarding treatment for B19 infection, 4 
patients received red cell transfusion, 4 patients received both platelet and red cell transfusions, one patient 
received IVIG alone and 7 patients received no treatment. In 3 cases, outcome was not stated; among the 
remaining 13 patients, there were 4 deaths which were due to relapse (n=1), secondary bacterial sepsis (n=2), 
and idiopathic pneumonia syndrome (n=1). The remaining 9 patients recovered. 
 
Studies of B19 infection in acute leukemia 
Table 3 summarises the results of various studies of B19 infection in acute leukemia. Where sufficient clinical 
details were included in these reports, specific patients were included in either Table 1 or Table 2, as 
appropriate. 
Broliden et al [18] tested the bone marrow of 59 unselected children with malignancies by PCR to detect B19 
DNA; 7 of 59 were positive, consisting ofALL on chemotherapy (n=3) (in one of these 3 cases, the presence of 
B19 was not associated with symptoms; the other two cases have been included in Table 1 as patient numbers 
16 and 17), ALL at onset (n=1) (patient no. 2 in Table 2), Non-Hodgkin´s lymphoma (n=2) and Ewing´s sarcoma 
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(n=1). Unfortunately, the total number of cases within each disease category of childhood malignancies was 
not available.  
El-Mahallawy et al [35] tested 50 ALL patients with anemia and 34 ALL patients without anemia (both groups 
were on maintenance therapy) for evidence of B19 infection. B19 DNA was positive in 11 of 50 ALL with anemia 
(of which, 4 were IgM+) compared with 2 of 34 ALL without anemia (none were serum anti-B19 IgM positive). 
Serum anti-B19 IgG was detected in 19/50 (38%) vs 15/34 (44%). 
Jitschin et al [36] studied malignant and non-malignant diseases for evidence of B19 infection at the time of 
admission. Of 24 ALL patients at the time of admission, 10 (41.6%) were serum anti-B19 IgG positive, 1 (4.2%) 
wasserum anti-B19 IgM positive and 16.7% were B19 DNA positive in either serum or bone marrow.  
Lindblom et al [37] documented bone marrow positivity for B19 DNA in 6/86 (7%) ALL patients at diagnosis and 
12/31 (39%) ALL patients during or between chemotherapy. Of the 6 B19 DNA+ ALL patients at diagnosis, 4 had 
anemia and 5 had thrombocytopenia.  
Soliman et al [38] documented B19 markers in 39 ALL patients and 20 patients with solid tumors, all 
undergoing chemotherapy and 30 normal controls. DNA was detected in 11/39, 5/20 and 0/30, respectively. 
Serum anti-B19 IgG was detected in 26/39, 10/20 and 18/30, respectively. Anti-B19 IgM was detected in 0/39, 
3/20 and 0/30, respectively. Patients positive for B19 DNA had significantly higher frequency of anemia, 
treatment with red cell transfusion, and longer hospital stay than B19 DNA negative patients.  
Zaki et al [39] demonstrated positivity for serum B19 DNA in 6 of 25 (25%) hemolytic anemia in aplastic crisis, 0 
of 20 hemolytic anemia without aplastic crisis, 6 of 20 acute leukemia patients during chemotherapy, 9 of 20 
(45%) recently diagnosed acute leukemia, and 0 of 20 normal controls. Serum IgM was detected in 9 of 25 
(36%) hemolytic anemia in aplastic crisis, 1 of 20 (5%) hemolytic anemia without aplastic crisis, 7 of 20 (35%) 
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acute leukemia patients during chemotherapy, 10 of 20 (50%) of recently diagnosed acute leukemia and 0 of 20 
normal controls. 
Zaki et al [40] demonstrated B19 DNA in serum and bone marrow of 9 of 48 (20%) ALL patients during 
chemotherapy as compared withnone of the controls. Serum anti-B19 IgM was detected in 12 of 48 (26.7%) 
ALL patients during chemotherapy as compared withnone of the controls, and IgG was detected in 18 of 48 ALL 
patients during chemotherapy as compared with 2 of 20 (10%) controls.  
Da Costa et al [41] tested patients with ALL, AML and chronic myeloblastic leukemia (CML) at diagnosis for B19 
DNA in bone marrow, and found positivity in 12 of 78 (15.4%) ALL, 25 of 155 (16.1%) AML and 3 of 16 (18.7%) 
CML. Multiple genotypes were found. Of the 40 participants, 25 (62.5%) were infected with genotype 1a and 
15 (37.5%) with genotype 3b; 12/40 (30%) of the leukemia patients were co-infected with genotypes 1a and 
3b. In addition, a new B19 virusintergenotypic recombinant (1a/3b) and an NS1 non-recombinant genotype 1a 
were detected in one patient. 
Heegaard et al [42] studied the serum of 65 patients with childhood ALL at onset for evidence of B19 infection 
and found none positive; one ALL patient was found to be positive for B19 DNA 5 months prior to diagnosis of 
ALL during an episode of pancytopenia. This case report has been reported in detail [32] and is included as 
patient no. 14 in Table 2. 
Heegaard et al [43] studied 75 ALL patients, 48 B19 seronegative and 27 B19 seropositive. 4 of 48 B19 
seronegative patients seroconverted, and exhibited viremia, which was associated with profound anemia and 
thrombocytopenia in all 4 patients. 
Ibrahem et al [44] documented IgG positivity in 19/40 new ALL patients and 12/60 normal controls. There was 
no association between presence of serum anti-B19 IgG and antibody to P53, but there was a significant 
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association between presence of serum anti-B19 IgG and the TEL-AML1 fusion gene (also known as ETV6-
RUNX1), as 10 (71.4%) of TEL-AML1 positive cases were positive for anti-B19 IgG.  
Kishore et al [45] studied 35 children with malignancy (22 acute leukemia and 13 lymphoma at presentation) 
and 34 children with solid tumors. Evidence of 6 active B19 infections were found (serum anti-B19 IgM 
positivity), of which 5occurred in ALL patients and one in a lymphoma patient.Among the five anti-B19 IgM 
positive patients, 2 were B19 DNA positive and in 2 cases, giant pronormoblasts were also seen in bone 
marrow.  
Zaki et al [46] demonstrated B19 DNA in serum of 10 of 45 (22%) ALL patients during chemotherapy, 18 of 40 
(45%) ALL of recent onset and 0 of 20 healthy controls. Serum anti-B19 IgM was detected in 14 of 45 (31%) of 
ALL patients during chemotherapy, 20 of 40 (50%) ALL patients of recent onset and 0 of 20 healthy controls. 
Serum anti-B19 IgG was detected in 18 of 45 (40%) ALL patients during chemotherapy, 16 of 40 (40%) ALL 
patients of recent onset, and 0 of 20 healthy controls. 
As regards the interpretation of these studies, as B19 virus persists indefinitely in various tissues, including 
blood and bone marrow, following acute infection, the clinical significance of detection of B19 DNA in the 
absence of recognised B19-associated symptoms  is not entirely clear. This is quite a different situation to the 
detection of B19 DNA in blood contemporaneous with the occurrence of B19-associated symptoms, such as 
aplastic crisis or erythema infectiosum, in those patients included in Table 2, for example, in which sufficient 
clinical data is provided to enable confirmation that the clinical course of each patient was significantly 
impacted by acute B19 infection.  
 
The pathogenesis of acute leukemia 
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A significant body of research supports the role of infection in the pathogenesis of acute childhood leukemia, 
and especially ALL. There are two main proposed infectious pathogenetic mechanisms which overlap 
somewhat. First, that childhood leukemia may result from infection with a specific infectious agent introduced 
into a population without herd immunity [47]. And second, that delayed exposure to common infections during 
infancy and childhood results in an increased risk of common pre-B cell ALL in children who harbor genetic 
mutations that result in the creation of a leukemic clone [48]. Such clones may then proliferate and expand 
into ALL upon stimulation with infections that occur later, some time after birth. Although there are many 
reports which support both of these hypotheses, there have been few proposed specific molecular 
mechanisms [1]. This sequence is summarized diagrammatically in Figure 1. 
A significant body of evidence supports the second hypothesis of Greaves[48], including epidemiological 
studies which used surrogate indicators of exposure to infections, including birth order, history of infections in 
individuals, attendance at day-care and play groups, and parental contacts with possible sources of infection in 
the workplace [49,50]. These studies have shown that reduced exposure in early life to common childhood 
infections, increases the risk of developing leukemia. It has been shown that population mixing is an important 
risk factor, which further strengthens the putative role for infection in the causation of childhood leukemia. It is 
hypothesized that delayed infection during infancy may be an important causal factor [1]. 
There are a few recorded clusters of childhood leukemia [50-52], however, the role of time-space clustering 
appears to be modest [50,51,53,54].  
There have been numerous studies of HLA associations in childhood acute leukemia[55]. Various class II HLA 
alleles have been shown to be risk factors for development of childhood acute leukemia, including HLA-
DPB1*0201 [56] and HLA-DR53, which is linked to carriage of HLA-DRB1*04, *07 and *09 alleles [57]. The 
supertypic specificity HLA-DR53 is encoded by theHLA-DRB4 locus in the HLA class II region. There was a 
moderate allelic association with the most common allele in the HLA-DR53 group, HLA-DRB1*04, in the whole 
11 
 
group that was stronger in males [57]. HLA-DRB1*15 and *16 have also been reported as predisposing 
alleles[58,59] and also HLA-DRB1*01 [60]. Interestingly, ancestral HLA analysis has shown that there are 2 
clades regarding the HLA-DR gene polymorphisms, and that DRB1*01, *04, *07, *09, *15, and *16 are grouped 
with DR4 and DR5, while DRB1*03, *08, *11, *12, *13 and *14 are grouped with DR3 [61]. Interestingly, HLA-
DRB1 alleles *01, *04, *07, *09, *15, and *16 have a net positive charge within the first hypervariable region, 
while HLA-DRB1 alleles *03, *08, *11, *12, *13 and *14 have a net negative charge within this region. The 
significance of this is considered below.  
Class I HLA associations with acute leukemia include HLA-B40 [62], HLA-A11, HLA-B38 and HLA-B49 [63]. Klitz et 
al[64] report a continuum of risk associations for HLA-A, HLA-B and HLA-DRB1,supporting the hypothesis that 
infection and the resulting immune response, is important in the pathogenesis of acute leukemia. 
Recently, it has been shown that interleukin-10 secretion is severely deficient in children who grow up to 
develop leukemia [65]. IL-10 is a strong anti-inflammatory cytokine secreted by monocytes and lymphocytes 
and is important in the limitation of cell-mediated immune reactions.It has been shown that IL-10 production 
attenuated an increased risk for repeated respiratory infections during infancy and childhood associated with 
elevated T cell IL-5 production at birth[66].It is possible that children with dysregulated immunefunction at 
birth are at higher risk for developing leukemia due to constitutively lowerexpression of IL-10, a cytokine that 
attenuates inflammatory responses [67]. 
Several studies and case reports indicate that asmall sub-group of ALL patientsundergo a previous phase of 
aplasia, which precedes development of overt ALL by 2-9 months [68,69]. This is almost always associated with 
infection and either remits spontaneously or responds to corticosteroids. In the few cases that have been 
studied, immunoglobulin or T cell receptor gene analysis have confirmed the presence of the leukemia, or pre-
leukemic, cells during this aplastic phase [70,71].  
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Pathogenesis of parvovirus B19 infection 
The pathogenesis of parvovirus B19 infection is complex, particularly when the less common clinical 
manifestations are included. Although the mechanisms are considered separately, clearly they donot occur 
separately in vivo, and during a single B19 infection, several of these mechanisms may be involved. Table 4 
summarises the pathogenetic mechanisms which have been documented during parvovirus B19 infection.  
B19 acquisition is usually by the respiratory route via aerosol droplet transmission from an acutely infected 
patient[75], however, B19 virus may also be transmitted parenterally by infected blood and blood 
products[74]. Initially, the virus is thought to multiply in the throat, leading to viremia on day 6, with infection 
of erythroblasts in the bone marrow[75,76]. Local viral replication is important in most clinical manifestations, 
except arthralgia, as virus has not been isolated from affected joints. The nonstructural protein (NS1) has been 
shown to be cytotoxic and NS1 cytotoxicity is thought to account for thrombocytopenia and leucopenia 
occurring during B19 infection[72]. B19 infection of erythroblasts results in apoptotic killing of infected cells 
and reticulocyte arrest[72,73], and this is important in transient aplastic crisis in patients with shortened red 
cell survival, erythema infectiosum, hydrops fetalis, chronic pure red cell aplasia, and aplastic anemia and other 
cytopenias, and may also be important in the pathogenesis of acute leukemia. Specific anti-B19IgG is produced 
from day 16 and this coincides with appearance of erythema infectiosum and arthralgia[75,76], which are 
thought to be mediated by immune complex deposition, at least in part. Appearance of serum anti-B19 IgG 
controls the infection, allowing recovery of erythroid cell production[74].  
 
A variety of autoantibodies are produced during acute B19 infection, including rheumatoid factor, antinuclear 
antibody, anti-keratin and anti-collagen II antibodies [84], and antiphospholipid antibody which has the same 
specificity as that produced in systemic lupus erythematosus [85].  
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Various class I and II HLA alleles are associated with occurrence of symptoms (principally arthralgia and rash) 
during parvovirus B19 infection. These were HLA-B49 and HLA-DRB1*01, *04, *07, *15 and *16 alleles [78,89]. 
In all symptomatic B19-infected subjects who carried the above HLA alleles, there was marked release of 
various cytokines, including TNF-α, IFN-γ, IL-6, granulocyte-macrophage colony stimulating factor (GM-CSF) and 
chemokine (C-C motif) ligand 2 (CCL2), and low levels of IL-10[101,102]. The B19 NS1 protein upregulates IL-6 in 
hemopoietic and endothelial cells, and this is mediated by the NF-KB site in the IL-6 promoter[81].  
 
In addition, in the setting of symptomatic B19 infection, production of antibody to the B19 nonstructural 
protein was associated with the IL-10 -819/-592*TA haplotype which mediates low IL-10 transcription [103]. 
 
Following acute infection, B19 virus persists in many different tissues, including skin, bone marrow, synovium, 
and liver, and it is believed that this is a life long phenomenon[104]. The possibility that the B19 genome may 
integrate into the human genome has been investigated, and although this has not been confirmed to occur in 
a similar fashion tothe integration of the related parvovirus, adeno-associated virus, the human genome does 
exhibit short footprints of the B19 genome in multiple human genes, the significance of which remains unclear 
[105].  
 
It has recently been shown that a particular pattern of DNA methylation among a subset of cancer genes was 
associated with a history of parvovirus B19 infection as detected by serum anti-B19 IgG but not anti-B19 IgM 
[100]. This finding suggests that B19 virus infection may drive specific DNA methylation patterns in susceptible 
B precursor cells, thus contributing to the leukemogenic potential of these cells, and these changes may be 
retained even after control of the infection [100].  
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Parvovirus B19 as a candidate viral trigger in the pathogenesis of acute leukemia 
We believe that parvovirus B19 is involved in the pathogenesis of a subset of cases of acute leukemia, and that 
B19 virus is one of a number of viral triggers. There are various features of parvovirus B19 which make it a 
candidate trigger infection in the pathogenesis of acute leukemia. The majority of the population becomes 
infected early in life in both developed and developing worlds, and so the possibility of delayed infection exists 
for B19 virus, as has been proposed as a possible mechanism in the pathogenesis of acute childhood 
leukemia[47]. Interestingly, in studies of B19 infection in childhood leukemia from Mansoura, Egypt, B19 
seroprevalence of the normal controls was zero [39,46] and 10% [40], respectively, which was much lower than 
B19 seroprevalence in cases of acute childhood leukemia, where it ranged from 40%-45%[39,40,46]. The 
reasons for this apparent delay in occurrence of B19 infection during childhoodin these studies deservefurther 
attention. 
B19 virus is erythrotropic and primarily targets erythroblasts in the bone marrow. However, it is also able to 
infect various other cell types. B19 infection may directly result in aplastic crisis in patients with shortened red 
cell survival, and this aplastic crisis has been shown to be a prodrome of ALL in 2% of patients[68,69]. There are 
7 case reports in the literature of B19-associated aplastic anemia, occurring several months prior to the onset 
of acute leukemia [27-33] and the clinical course of these cases is summarized in Table 2.  
Symptomatic B19 infection has been shown to be associated with HLA-B49 and HLA-DRB1*01, *04, *07, *15 
and *16 alleles[78,89]. All symptomatic parvovirus-associated HLA-DRB1 molecules carry a neutrallycharged 
glutamine at position 10 and a positively charged lysine at position 12 of the first hypervariable region (HVR), 
conferring a net postive charge to this region.HLA-DRB1 molecules with a positively charged firstHVR, include 
*01, *04, *07, *09, *15 and *16. These associations were demonstrated for both males and females. HLA-B49 
[63] and the above HLA-DRB1 molecules with a positive charge in the first HVR, have been associated with 
development of childhood ALL[57-59,63]. In fourpublished cases of B19 infection present at the time of 
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diagnosis of acute childhood leukemia, each patient carried at least one HLA-DRB1 allele with a positive charge 
in the first HVR[26]. Table 5 shows the net charge in this first HVR for all HLA-DRB1 molecules, and relates this 
to known class II associations in acute leukemia, symptomatic parvovirus B19 infection and B19-associated 
acute leukemia. 
 
Acute symptomatic B19 infection has been  associated with raised circulating levels of TNF-α, IFN-γ, IL-6, GM-
CSF and CCL2, and low levels of IL-10; these pro-inflammatory cytokines remain at elevated levels for up to 3 
years following the time of acute infection [101,102]. Proinflammatory cytokines have been shown to be 
elevated during the prodrome and onset of acute childhood leukemia, and ALL cells express multiple pro-
inflammatory cytokine receptors. In addition, interleukin-10 secretion is severely deficient in children who 
grow up to develop leukemia [65]. Development of antibody to the parvovirus B19 nonstructural protein, 
which is associated with more severe courses of infection, has been associated with the IL-10 -819/-592*TA 
haplotype which mediates low IL-10 transcription [103]. This is consistent with a heightened immune response 
in a subset of parvovirus infected persons with particular genetic determinants, and this may also be important 
in the putative role for parvovirus B19 in the pathogenesis of acute leukemia.  
It has recently been shown that a particular pattern of DNA methylation among a subset of cancer genes was 
associated with a history of parvovirus B19 infection as detected by serum anti-B19 IgG but not anti-B19 IgM 
[100]. This finding suggests that B19 virus infection may drive specific DNA methylation patterns in susceptible 
B precursor cells, thus contributing to the leukemogenic potential of these cells, and these changes may be 
retained even after control of the infection [100].  
 
 
Perspective: viral causes of cancer 
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Several viruses have been shown to cause human cancer and these are therefore known as oncoviruses. These 
include Epstein-Barr virus, hepatitis B virus, hepatitis C virus, human T-cell lymphotropic virus, human 
papillomaviruses, Kaposi´s sarcoma-associated herpesvirus (human herpesvirus 8) and Merkel cell 
polyomavirus (Table 6)[106,107]. Following acute infection, oncoviruses generally cause little or no disease or 
non-neoplastic diseases in their respective hosts, and persist indefinitely. Oncoviruses may have a genome 
consisting of DNA (Epstein-Barr virus), RNA and DNA (human T-lymphotropic virus and hepatitis B virus), or 
RNA (hepatitis C virus). Some oncoviruses persist as circular episomes or plasmids and replicate separately 
from host cell DNA (Epstein-Barr virus and Kaposi´s sarcoma herpesvirus) while other oncoviruses integrate 
into the host genome (polyomavirus and papillomavirus). Direct viral oncogenicity involves insertion of viral 
genes into the host cell or enhancement of the activity of pre-existing proto-oncogenes in the host genome. 
Indirect viral oncogenicity involves chronic non-specific inflammation occurring over decades following acute 
infection[106,107].  
Members of the Parvoviridae have a DNA genome and persist indefinitely following acute infection which may 
or may not be manifested clinically. Parvovirus B19 persists in many different erythroid and non-erythroid 
human tissues following acute infection, including bone marrow, colon, heart, skin, liver, lymphoid, synovial, 
testicular and thyroid tissues. However, the mode of persistence of B19 virus is not yet fully understood. The 
B19 NS1 protein has been shown to upregulate transcription of both IL-6 [81] and TNF-α [108], and an 
increased inflammatory response has been demonstrated in some of the above tissues in association with 
expression of either B19 mRNA or proteins [109].  
Therefore, there are certain aspects of the life cycle of parvovirus B19 which could fit with those of an 
oncovirus. However, certain parvoviruses, such as the rat parvovirus H-1,have been shown to be oncolytic in 
humans [110]. Rat parvovirus H-1 (ParvOryx) is currently undergoing clinical trials as a treatment for human 
glioblastoma multiforme [111].   
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Conclusions 
Parvovirus B19 infection may complicate the clinical course of acute leukemia by opportunistic infection which 
may be acquired exogenously or represent reactivation of latent B19 virus. However, acute B19 infection may 
precede a diagnosis of acute leukemia by up to 180 days, and in some cases is associated with aplastic crisis, 
which is already recognized to precede development of acute leukemia in a small percentage of cases. B19 
virus is a recognized cause of aplasia, the pathogenesis of which is by direct infection of erythroblasts and B19-
mediated apoptosis, less frequent infection of other bone marrow cell types, NS1-mediated cytotoxicity of 
bystander cells, and pro-inflammatory cytokine secretion. In addition, there is evidence of delayed infection 
with B19 virus in some studies, HLA class I and II associations which match those recognized to predispose to 
development of acute leukemia, cytokine dysregulation and a particular pattern of DNA methylation of cancer 
genes which is associated with positivity for serum anti-B19 IgG.  
Epidemiological studies suggest that the pathogenesis of acute leukemia involves an unusual response to an 
ubiquitous virus infection usually acquired during childhood. Other childhood virus infections that have been 
linked with acute leukemia includehuman herpesvirus 6, cytomegalovirus and Epstein-Barr virus. Human 
herpes virus 6 was first isolated from the B lymphocytes of patients with lymphoproliferative disorders 
including one patient with acute lymphoblastic leukemia [112], and was subsequently shown to have 
oncogenic potential [113] and high viral loads were found in lymphoproliferative diseases [114] However, there 
is no significant difference in either seroprevalence or nucleic acid prevalence in patients with acute leukemia 
as compared with controls [115-117].  
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Infectious mononucleosis and positivity in the monospot test have been shown to occur both preceding and at 
the time of the diagnosis of acute monocytic leukemia [118,119]; 20 cases of infectious mononucleosis-
associated acute monocytic leukemia are reviewed in the report by Pedersen et al [119]. Anothersimilar case 
was shown to be caused by varicella-zoster virus infection [120]. Infectious mononucleosis may be caused by 
Epstein-Barr virus, cytomegalovirus and varicella-zoster virus. Epstein-Barr virus infection may also masquerade 
as acute monocytic leukemia [121]. However, despite this interesting association, the nucleic acid prevalences 
of Epstein-Barr virus, cytomegalovirus and human herpesvirus 6 were found to be 14%, 19%, and 9%, 
respectively [116], which was taken as evidence against the involvement of these infectious agents in acute 
leukemia. However, it is difficult to assign pathogenetic significance to the presence of a virus which persists 
following the acute phase, because the timing of the acute infection and its consequences are unknown at the 
time of testing.  
These authors believe that each case of acute leukemia may be triggered by one of several viruses, including 
parvovirus B19, and that to identify which virus infection is responsible for a particular case of acute leukemia, 
it would be necessary to study very large population cohorts, in order to identify the timing of seroconversion 
to particular viruses occurring contemporaneous with the diagnosis of different types of acute leukemia.  
We believe that the current management of parvovirus B19 infections is probably adequate although 
awareness of the possibility that B19 infection may precede or be contemporaneous with diagnosis of acute 
leukemia could certainly be improved.  
Despite a lot of high quality research in the area of acute childhood leukemia, a particular model of infection 
with its associated pathogenetic mechanisms has been lacking. Similar to the pathogenesis of other chronic 
inflammatory and autoimmune diseases, it is most unlikely that B19 virus is the only infectious agent which 
may trigger an outcome of acute leukemia, but that individual presentations of acute leukemia may 
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betriggered by one of a range of viruses. However, the recognition of B19 infection as one particular trigger for 
the disease in a subset of patients, provides a useful model for further study of this intriguing relationship.  
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Figure 1 Legend 
A model of the time course and important events in the pathogenesis of parvovirus B19-associated childhood 
acute lymphoblastic leukemia (ALL). 
Initiating mutations occur at a frequency of approximately 1% of normal live births, and among these a second 
activating mutation occurring after birth in the same cell that harbors the initiating mutation is rare, occurring 
only in those with an increased potential to react vigorously to early life infections, who have also had a 
reduced level of exposure to early life infections. According to this model, infection occurs and hematopoiesis 
is suppressed, allowing the selective outgrowth of pre-leukemic clones, one of which acquires the activating 
mutation, and with rapid proliferation, develops into ALL. In this model, the infection is by parvovirus B19, 
which is known to cause reticulocyte arrest and aplastic anemia, and in some individuals, to elicit a vigorous 
immune response with the potential to further suppress hematopoiesis by the action of cytokines. This figure 
was adapted from Figure 2 of the review of Greaves [1] and Figure 3 of the review of Wiemels [67]. 
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Table 1. Case reports of B19 infection in acute leukemia during chemotherapy 
                
Case 
No. 
Leukemia 
type* 
Past 
Medical 
History** 
Age Sex Bone marrow at 
presentation 
Leukemia 
Treatment 
status at time 
of B19 infection 
Interval 
between 
leukemia 
diagnosis 
and B19 
onset 
B19 symptoms, 
signs & markers† 
Hemoglobin 
at time of 
B19 infection 
(g/dL) 
Platelets  
109/L 
White 
Blood 
Count 
109/L 
Neutro
phils  
109/L 
Treatm
ent for 
B19 
infectio
n§ 
Hemoglobi
n post-B19 
infection 
(g/dL) 
Reference 
number 
                
                
1 ALL  NF-1 12 M Hypercellular with 
immature cells 
Induction  14d BM - GPNB, 
erythroblastopenia 
10.8 2.44 6.0 ? -  4 
2 ALL  38 M Hypocellular, 
erythroblastopenia 
Induction  30d BM - GPNB, 
erythroblastopenia 
IgM+ 
9.6 900 0.648 28.2% IVIG 12 5 
3 ALL Spherocy
tosis 
13 F Not stated Maintenance  Not 
stated 
Aplastic crisis ? ? ? ? ? ? 6 
4 ALL  6 F Lymphoblasts Induction  36d D46 BM – GPNB, 
erythroblastopenia 
DNA+ 
8.0 5.0 ? 0 RCT, 
IVIG 
9.7 7 
5 ALL  3 M Not stated Maintenance  2y DNA+ ? low ? ? ? ? 8 
6 ALL  2.5 F Pancytopenia Maintenance  20m DNA+, IgM+, IgG+  
CSF – DNA+ 
10.0 92 1.6 55% - ? 9 
7 ALL  6 M Not stated Maintenance  Not 
stated 
BM – GPNB, 
erythroblastopenia 
7.0 low ? ? IVIG Normal 10 
8 ALL  8 F Not stated Maintenance  Not 
stated 
IgM+, DNA+ <5.0 low low ? RCT, 
IVIG 
Normal 11 
9 ALL  22 F Not stated Maintenance  6y Erythroblastopenia 
IgG+, DNA+ 
8.0 ? ? ? RCT, 
IVIG 
14.0 12 
10 ALL  17 M 90% lymphoblasts Between 
chemotherapy 
8m BM – GPNB, 
erythroblastopenia 
IgM+, IgG+, DNA+ 
9.6 64 normal normal RCT Normal 13 
11 ALL  FAB:L2 42 F Not stated Maintenance  reticulocytopenia,   
BM – GPNB, 
erythroblastopenia. 
B19 antigen + 
6.4 69 ? ? none Normal 14 
12 ALL  4 M Not stated Maintenance 3y 7m B19 – GPNB, 
Erythroblastopenia 
B19 markers –ve 
Later – IgM+, IgG+  
5.8 408 6.4 40% RCT 11.0 15 
13 ALL  ? ? Not stated Maintenance 6m Erythroblastopenia 
DNA+, EM+ 
4.7 656 2.1 ? RCT 11.5 15 
14 ALL  9 M Lymphoblasts Maintenance  22m BM – erythroid 
hypoplasia, DNA+ 
8.8 58 25.1 ? RCT, 
IVIG 
? 16 
15 ALL  10 M Not stated Maintenance  1y BM – GPNB, 
erythroid 
hypoplasia, IgM+, 
IgG+, DNA+ 
6.5 119 1 ? Chemo 
stoppe
d 
Normal 17 
16 ALL  10 F Not stated Maintenance  15m Fever, rash, DNA+, 7.4 76 0.3 0 Chemo ? 18 
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IgM+ stoppe
d 
17 ALL  3 F Not stated Maintenance 18m Conjunctivitis, 
lethargy, DNA+, 
IgM+ 
7.9 normal normal normal Chemo 
stoppe
d 
? 18 
18 B-ALL  4 F Not stated Maintenance 7m erythroid 
hypoplasia, IgM+, 
DNA+ 
5.8 89 0.8 0.448 - Resolution 19 
19 B-ALL, HLH  3 M 93% lymphoblasts Maintenance  14m BM – GPNB, 
erythroid 
hypoplasia, DNA+, 
IgM+ †† 
8.9 98 1.2 11.5% IVIG, 
Steroid 
Resolution 20 
20 Pre-B ALL  1 M Immature blasts Maintenance, in 
complete 
remission 
14m BM – GPNB, 
erythroid 
hypoplasia, DNA †† 
8.4 18 13.4 ? RCT Resolution 
at 1yr 
16 
21 Pre-B ALL  5 M Not stated Maintenance  26m IgM+, IgG+, DNA+ 
Acute hepatitis 6m 
earlier, DNA 
detected at 102 
7.2 19 0.5 0 RCT, 
IVIG 
13.2 21 
22 Pre-B ALL  12 F Not stated Maintenance  23m BM – GPNB, 
erythroid 
hypoplasia, DNA+ 
6.4 88 1.2 0.720 RCT, 
IVIG 
12.0 21 
23 Pre-B ALL  7 F Not stated Maintenance  16.5m DNA++ 8.0 38 1.1 0.451 IVIG 8.8 21 
24 Pre-B ALL  4 M Not stated Maintenance  16m DNA+ †† 5.2 54 1.4 0.308 IVIG 12.6 21 
25 Pre-B    ALL  8 M Not stated Maintenance  22.75m Fever, rash, DNA+ 11.6 235 6.5 0.986 IVIG 12.3 21 
26 AML-M6b CML  bcr-
abl+ 
12 F Not stated Splenectomy >1y BM – 80% GPNB, 
death in 1 week 
3.0 20 55 ? - - 22 
27 LGLL  65 F Not stated - 14y BM – diffuse 
lymphocytosis, 
reduced erythroid 
precursors. IgM+ 
IgG- 
7.0 ? ? ? IVIG, 
RCT, 
steroid 
Transfusion 
dependent 
23 
28 LGLL-NK  42 F Not stated - 4y BM – diffuse 
lymphocytosis, rare 
erythroid 
precursors. IgM+ 
IgG- 
8.0 ? ? ? IVIG, 
RCT 
Resolution 23 
29 CTCL  30 F Not stated  13y BM – 
lymphocytosis, 
decrease in 
erythroid 
precursors. IgM+ 
IgG- 
7.5 normal normal low RCT Resolution 23 
                
                
*ALL, acute lymphoblastic leukemia; AML, acute myeloblastic leukemia; HLH, hemophagocytic lymphohistiocytosis; LGLL, large granular lymphocyte leukemia; NK, natural killer cell type; CTCL, chronic T cell lymphocytosis. 
**NF-1, neurofibromatosis type-1, CML, chronic myeloblastic leukemia.  
†BM, bone marrow; GPNB, giant pronormoblasts.  
††contact with erythema infectiosum 
§IVIG, intravenous immunoglobulin; RCT, red cell transfusion.  
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Table 2. Case reports ofB19 infection in acute leukemia prior to or at the time of diagnosis 
                 
Case 
No. 
B19-
associated 
prodrome 
Leukemia 
type* 
Age Sex Clinical 
presentation** 
B19 markers 
at 
presentation 
Bone marrow 
at acute B19 
infection† 
Hemoglo
bin at 
presenta
tion 
(g/dL) 
Platele
ts 
109/L 
White 
Blood 
Count  
109/L 
Neutrophi
ls 
109/L 
Interval 
between B19 
infection and 
leukemia 
onset (days) 
Rx for 
B19†† 
Outcome Other Referenc
e number 
                 
                 
1 - T-ALL 
Bcr-abl+ 
16y M Septic shock, 
pancytopenia 
DNA+, IgG+  8.2 90 2.5 0 0 - Death due to 
idiopathic 
pneumonia 
syndrome 
 24 
2 - ALL 4y F Petechiae, Hep-
spl 
DNA+, IgG+  11.2 18 15 Not stated 0 Plat tx 
RCT 
Difficult, 
delayed 
chemotherapy 
Down 
Syndrome 
18 
3 - ALL 16m F Ataxia, 
nystagmus, 
tremor, 
weakness 
IgM+ GPNB 12.2 345 13 25% 0 IVIG gradual 
recovery 
 25 
4 - Pre-B ALL 13m F Fever, orbital 
edema 
IgM+  10.0 417 2.8 19% 0 - Not stated  25 
5 - Common 
ALL 
7y 
2m 
F Pallor, scalp 
swelling 
DNA+, IgG+ Lymphoblasts 
& Erythroid 
hypoplasia 
5.4 130 2.3 - 1 RCT Remission 
post-
chemotherapy 
 26 
6 - AML M7 1y 
6m 
F Pallor, rash, 
pancytopenia, L, 
leg pain, hep-spl 
DNA+, IgM+, 
IgG+ 
Lymphoblasts 
& Erythroid 
hypoplasia 
4.2 58 1.1 - 1 Plat tx, 
RCT 
Death due to 
relapse 
 26 
7 - Common 
ALL 
6y 
11m 
F Polyarthralgia, 
fever, rash, L, 
hep-spl, pallor 
DNA+, IgM+, 
IgG+ 
Lymphoblasts 
& Erythroid 
hypoplasia 
3.0 11 17 - 3 Plat tx, 
RCT 
Remission 
post-
chemotherapy 
 26 
8 - Null cell 
ALL 
2y 
3m 
M Cough, fever, 
pallor, L, hep-spl 
DNA+, IgG+ Lymphoblasts 
& Erythroid 
hypoplasia 
5.5 411 60 low 3 RCT Death during 
chemo, bac 
sepsis 
 26 
9 Aplastic 
crisis 
AML 18m M Fever, pallor IgM+ Pancytopenia, 
GPNB 
3.6 199 3.2 18% 14 RCT Remission 
post-
chemotherapy 
Orbital 
sarcoma 
27 
10 Aplastic 
crisis 
ALL 7y M Fever, arthralgia, 
rash, hep-spl, L 
- Lymphoblasts 
& Erythroid 
hypoplasia 
7.3 238 12.5 43% 40 - Chemo with 
remission 
Sezary 
cells and 
monocyte
s in skin 
biopsy 
28 
11 Aplastic 
crisis 
ALL 1y F Fever, L, pallor, 
Hep-spl, 
IgM+, IgG+ Erythroid 
hypoplasia, 
myeloblasts 
2.6 243 3.6 0.25 63 - Not stated  29 
12 Aplastic 
crisis 
ALL-type 1  
Ph1+ 
23y F Back pain, fever IgM+ necrosis 8.0 3 2.4 48% 63 - Chemo with 
remission 
Considere
d for BMT 
30 
13 Aplastic 
crisis 
AML 13m M Not stated DNA+, IgM+, 
IgG+ 
Pancytopenia, 
megakaryocyti
c blasts 
3.1 <10 3.3 0.7 75 - Recovery at 
47weeks, post-
chemo 
Downs 31 
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14 Pre-B ALL ALL 2y F Tonsillitis, fever, 
recurrent rash 
DNA+, IgG+ pancytopenia 4.5 34 3.4 0.1 150 Plat tx, 
RCT 
Recovery at 5 
years 
TCR & IgH 
gene 
rearrange
ment 
32 
15 Aplastic 
crisis 
EL 69y M Fever, 
pancytopenia 
IgM+, IgG+ GPNB, 
pancytopenia, 
myeloblasts, 
monocytic 
blasts, B19 
DNA- 
8.9 low low low 180 RCT Death due to 
infection 
Multinucle
ated giant 
cells, 
fused 
erythroid 
cells, 
33 
16 - T-LGLL 33y F Fever, 
polyarthralgia 
IgM+, DNA+ Hypocellular, 
GPNB 
7.6 192 2.0 36% 0 - Not stated TCR gene 
rearrange
ment 
34 
                 
                 
*ALL, acute lymphoblastic leukemia; AML, acute myeloblastic leukemia; Ph1, Philadelphia chromosome; EL, erythroleukemia, T-LGLL, T cell large granular lymphocyte leukemia. 
**Hep-spl, hepatosplenomegaly; L, lymphadenopathy. 
†GPNB, giant pronormoblasts. 
††plat tx, platelet transfusion; RCT, red cell transfusion; IVIG, intravenous immunoglobulin; BMT, bone marrow transplant; TCR, T cell receptor.  
Mother also had these B19 markers 
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Table 3. Studies of B19 infection in acute leukemia  
       
  Parvovirus B19 Markers    
  No. subjects (percentage)    
       
       
 
Clinical category 
(Number of subjects) 
Bone 
marrow B19 
DNA 
Serum 
B19 DNA 
Serum anti-
B19 IgM 
Serum anti- 
B19 IgG 
Country of 
origin 
Reference 
       
       
Acute Lymphoblastic Leukemia on chemotherapy (? total) 3    Sweden 18 
Acute Lymphoblastic Leukemia at onset (? total) 1      
Non-Hodgkin´s Lymphoma (? total) 2      
Ewing´s sarcoma (? total) 1      
n=59       
       
Acute Lymphoblastic Leukemia with anemia (50) 11 (22%)  13 (26%) 19 (38%) Egypt 35 
Acute Lymphoblastic Leukemia without anemia (34) 2 (6%)  2 (6%) 15 (44%)   
       
Acute Lymphoblastic Leukemia (24) 1 (4.2%) 4 (16.7%) 1 (4.2%) 10 (41.6%) Germany 36 
Acute Myeloblastic Leukemia (3) 0 0 1 (33.3%) 1 (33.3%)   
Chronic Myeloblastic Leukemia (2) 0 0 0 0   
Myelodysplastic Syndrome (2) 1 (50%) 1 (50%) 0 2 (100%)   
       
Acute Lymphoblastic Leukemia at onset (86) 6 (7%)    Sweden 37 
Acute Lymphoblastic Leukemia  on chemotherapy (31) 12 (39%)      
       
Acute Lymphoblastic Leukemia on chemotherapy (39)  11 (28%) 0 26 (67%) Egypt 38 
Solid tumors, on chemotherapy (20)  5 (25%) 3 (15%) 10 (50%)   
Normal controls (30)  0 0 18 (60%)   
       
Hemolytic anemia, aplastic crisis (25)  6 (25%) 9 (36%) 14 (56%) Egypt 39 
Hemolytic anemia, no crisis (20)  0 1 (5%) 7 (35%)   
Acute leukemia, on chemotherapy (20)  6 (30%) 7 (35%) 9 (45%)   
39 
 
Acute leukemia, at onset (20)  9 (45%) 10 (50%) 8 (40%)   
Normal controls (20)  0 0 0   
       
Acute Lymphoblastic Leukemia on chemotherapy (48) 9 (20%) 9 (20%) 12 (26.7%) 18 (40%) Egypt 40 
Normal controls (20) NT 0 0 2 (10%)   
       
Acute Lymphoblastic Leukemia  at onset (78) 12 (15.3%)    Brazil 41 
Acute Myeloblastic Leukemia at onset (155) 25 (16.1%)      
Chronic Myeloblastic Leukemia at onset (16) 3 (18.8%)      
       
Acute Lymphoblastic Leukemia at onset (65)  1 (1.5%)   Denmark 42 
       
Acute Lymphoblastic Leukemia at onset (75)    4 of 48 IgG -
seroconverted 
Denmark 43 
       
Acute Lymphoblastic Leukemia at onset (40)    19 (47.5%)* Iraq 44 
Normal controls (60)    12 (20%)   
       
Acute Lymphoblastic Leukemia at onset (18)   5 (28%)  India 45 
Acute Myeloblastic Leukemia (4)       
Lymphoma (13)   1 (8%)    
Solid tumors (34)   0    
       
Acute Lymphoblastic Leukemia on chemotherapy (45)  10 (22.2%) 14 (31.1%) 18 (40%) Egypt 46 
Acute Lymphoblastic Leukemia (30)       
Acute Myeloblastic Leukemia (15)       
Acute Lymphoblastic Leukemia at onset (40)  18 (45%) 20 (50%) 16 (40%)   
Acute Lymphoblastic Leukemia (24)       
Acute Myeloblastic Leukemia (16)       
Normal controls (20)  0 0 0   
       
* 10 TEL-AML1 positive cases (71.4%) had anti-B19 IgG; †Patients with viremia at diagnosis or during therapy for infection had lower viral loads (median viral load, 7x10
4
 copies/mL) than did those 
who became viremic during maintenance therapy (median viral load, 2x10
8
 copies/mL). 
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Table 4. Documented pathogenetic mechanisms important during parvovirus B19 infection which may be relevant to the pathogenesis of acute childhood 
leukemia. 
           
 Local viral 
replication† 
Erythroblast 
apoptosis** 
NS1 
cytotoxicity‡ 
Immune 
complex 
deposition¶ 
Autoantibody 
production†† 
HLA 
associations§ 
Cytokine 
upregulation‡‡ 
Persistence& 
reactivation¶¶ 
Methylation 
of cancer 
genes 
References 
           
           
Common clinical manifestations*           
TAC + +        72-74 
EI + + + +  +    72,75-78 
Hydrops fetalis + +        79,80 
Arthralgia/arthritis   ? +  + ?   74,75,77,81-86 
Chronic PRCA + +      +  72,83 
           
Less common clinical 
manifestations 
          
Skin eruptions +    ?  ? +  74,75,77,81,84-86 
Meningoencephalitis +      +   87-89 
Vasculitis +   ? ?  ?   90-97 
Aplastic anemia/cytopenias + + +    + +  72,81,98,99 
Acute leukemia + + ?   ? + ? + 26,78,100 
           
*TAC = transient aplastic crisis; EI = erythema infectiosum; PRCA = pure red cell aplasia. 
†Local B19 replication occurs primarily in the erythroblasts, but also occurs in macrophages, myeloid cells, lymphocytes, hepatocytes, and dendritic epidermal and 
endothelial cells. 
**Erythroblast apoptosis, mediated by the NS1 protein, occurs in TAC, EI, and hydrops fetalis and probably also in PRCA and aplastic anaemia/cytopenias. 
‡B19 NS1 cytotoxicity is thought to account for haematological abnormalities in EI and cytopenias and possibly for arthralgia/arthritis. 
¶Immune complex deposition is thought to account for the rash of EI, arthralgia, peripheral neuropathy and may contribute to other B19 associated skin rashes and 
vasculitis. 
††Anti-B19 VP1 IgG cross reacts with collagen II and keratin, which may be significant in the pathogenesis of arthritis and skin pathology, respectively. Antiphospholipid 
antibodies occur after B19 infection and may be important in the pathogenesis of autoimmunity. 
§HLA-B49 and HLA-DRB1*01, *04, *07, *15 and *16 have been shown to be linked with symptomatic B19 infection.  
‡‡Upregulation of human IL6, mediated by the NS1 protein, may be important in aplastic anaemia/cytopenias and B19 associated arthritis, and skin rashes. 
¶¶Persistence of B19 is important in PRCA, may be important in B19 associated skin rashes, arthritis, CFS, RA, SLE, and vasculitis. 
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Table 5. Protein sequence alignments encoded by different HLA-DRB1 alleles, showing the charge at the first hypervariable region, amino acids 9–13, and 
associations with acute leukemia and symptomatic parovirus B19 infection, respectively. 
 
       
HLA-DRB1 allele Amino acids at 
positions 9-13 
Charge for each 
amino acid at 
positions 9-13* 
Net charge Association with acute 
leukemia 
(Reference no.) 
Association with 
symptomatic parvovirus 
B19 infection 
(Reference no.) 
Association with acute 
leukemia in which B19 
virus was detected at 
time of diagnosis of 
leukemia (4 patients) 
(Reference no.) 
       
       
*0101 WQLKF n n n + n + 60 78  
*0301 EYSTS - n n n n -    
*0401† EQVKH - n n + + + 57 78 26 
*0701† WQGKY n n n + n + 57 78 26 
*0801 EYSTS - n n n n -    
*0901† (rare allele) KQDKF + n - + n + 57   
*1001 EEVKF - - n + n -    
*1101 EYSTS - n n n n -    
*1301 EYSTS - n n n n -    
*1501 WQPKR n n n + + + 58,59 89 26 
*1601 WQPKR n n n + + + 58,59 89 26 
       
*n, neutral 
† HLA-DRB4 is one of the expressed HLA loci, which exists only on haplotypes possessing HLA-DRB1*04, *07, and *09 
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Table 6. Viruses that cause human cancer[106,107]. 
   
Human oncovirus Genome Human cancer 
   
   
Epstein-Barr virus DNA Burkitt´s lymphoma, Hodgkin´s lymphoma, Post-transplant lymphoproliferative 
disease, Nasopharyngeal carcinoma 
Hepatitis B virus DNA / RNA Hepatocellular carcinoma 
Hepatitis C virus RNA Hepatocellular carcinoma 
Human T-lymphotropic virus  DNA / RNA Adult T-cell leukemia 
Human papillomaviruses DNA Cancer of cervix, anus, penis, vulva, vagina and oropharynx 
Kaposi´s sarcoma herpesvirus / Human herpesvirus 8 DNA Kaposi´s sarcoma, primary effusion lymphoma, multicentric Castleman´s disease 
Merkel cell polyomavirus DNA Merkel cell carcinoma 
   
 
